Publications by authors named "Ida Marie Lind Rasmussen"
Article Synopsis
- Patient-reported outcome measures (PROMs) that assess health-related quality of life (HRQOL) are increasingly important in renal cell cancer (RCC) clinical trials for drug approval and policy making.
- The review identified 48 studies, mostly randomized controlled trials, that utilized 27 different PROMs, but only a small fraction were specifically designed for kidney cancer patients; 46% didn’t use any RCC-specific PROMs at all.
- The most commonly used PROMs focused on issues like pain, fatigue, and sleep quality, highlighting a lack of consistency in the tools used, which complicates the comparison of findings across studies.
Introduction: Many studies using Patient-reported outcomes (PRO) data have been conducted to monitor symptoms and health-related quality of life during follow-up after cancer treatment. However new ways of using (e)PROs have emerged. We aimed to explore the Danish landscape of the use of PRO in a research setting, where PRO is used actively in cancer patients undergoing treatment, and give an overview of how it is embraced by patients and clinicians.
View Article and Find Full Text PDFIndividualizing the Oncological Treatment of Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma by Using Gene Sequencing and Patient-Reported Outcomes: Protocol for the INDIGO Study.
JMIR Res Protoc
September 2022
Background: No phase 3 studies have yet been conducted for patients with non-clear cell (CC) renal cell carcinoma (RCC) exclusively due to the rare occurrence of the disease and the heterogenicity in tumor morphology. Consequently, there is no evidence of the optimal treatment, and new approaches are needed. One approach is individualizing treatment based on the gene sequencing of tumor tissue.
View Article and Find Full Text PDF